EBS Q1 2020 Earnings — Emergent BioSolutions Inc. Revenue & Financial Results | Market Cap Arena

EBSEmergent BioSolutions Inc.

$433M

Q1 2020 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$193M+1.0% YoY

Gross Profit

$74M38.2% margin

Operating Income

-$12M-6.0% margin

Net Income

-$13M-6.5% margin

EPS (Diluted)

$-0.24

QoQ Revenue Growth

-42.7%

Cash Flow

Operating Cash Flow

$58M

Free Cash Flow

$34M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$2.3B

Total Liabilities

$1.2B

Stockholders' Equity

$1.1B

Cash & Equivalents

$182M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$193M	$191M	+1.0%
Gross Profit	$74M	$53M	+39.5%
Operating Income	-$12M	-$27M	+57.4%
Net Income	-$13M	-$26M	+51.9%

Revenue Segments

Product

$148M77%

Contracts and Grants

$23M12%

Contract Development And Manufacturing

$22M11%

Geographic Segments

Non-US

$107M55%

UNITED STATES

$86M45%